PATENT CLAIM ANALYSIS

Application Number: 16221650
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-07
Patent Classification: ["514", "274000"]

Abstract:
The present disclosure relates to mdm2 inhibitors for use in specific dosing schedules. It was found that if sufficiently potent or, in alternative, sufficiently high dose of a Mdm2 inhibitor is used, it can cause antineoplastic effect by triggering much longer lasting antiproliferative mechanism in cells. The long lasting effect can sustain for several weeks after a single dose, which eliminates the need for daily treatment and allows administering the Mdm2i intermittently. A treatment with the intermittent dosing schedule of a Mdm2 inhibitor can be combined with a daily treatment of the Mdm2i or with another pharmaceutically acceptable ingredient.

Claim (Index 2):
The method of treatment according to  claim 1 , wherein the MDM2i is (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 98.0
- Lexical Diversity: 1.48611
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15914479', '13988227', '13298351', '14647939', '11942660']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.782881415355388
- 35 USC 102 Novelty (BERT): 0.5393158253849515
- Combined Prediction Score: 0.7585248563583444
- Mean Citation Score: 274.06664600000005
- Max Citation Score: 378.1278
- Similarity Product: 319.5809734742403

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test